PMA
4-methoxyamphetamine
Viewing r1 — Apr 25, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
PMA (para-methoxyamphetamine) is a synthetic empathogen of the phenethylamine class. It is structurally related to MDMA, distinguished by potent MAO-A inhibition and significantly greater toxicity.[1] PMA is a SERT substrate and MAO-A inhibitor, producing its effects by simultaneously releasing serotonin, blocking its reuptake, and preventing its breakdown.[2][3][4]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
MDMA, PMMA, MDA +1 moreMDMA, PMMA, MDA, 4-MTA show less
First described circa 1946, PMA entered illicit markets around 1970 as a substitute for MDA and LSD.[5] Recurring death clusters followed — Ontario 1973, South Australia in the 1990s,[6] England and Wales 2012–2013 — almost invariably when PMA was sold as MDMA in ecstasy tablets. It remains Schedule I in the United States and carries the highest control level in virtually every jurisdiction where it appears.
Subjective effects include moderate stimulation, emotional warmth, anxiety, and visual disturbances.[7] The experience is less rewarding and more physically punishing than MDMA — muted entactogenic warmth overlaid with pronounced cardiovascular strain and hyperthermia risk.[8] Nausea, agitation, and dangerous overheating are characteristic unsought effects.
PMA shows low abuse liability[9] but extreme acute toxicity, with one of the narrowest margins between active and fatal doses among recreational substances. The defining danger is its delayed onset[10]: users expecting MDMA-like effects redose before PMA takes hold, producing catastrophic serotonin accumulation and lethal hyperthermia.[11][8] No clinical trials have been conducted; the evidence base rests on forensic case reports, animal studies, and in vitro pharmacology.
History[edit]
Discovery
Para-methoxyamphetamine was first described in the scientific literature circa 1946.citation needed It received little academic attention until the early 1970s, when its appearance on illicit drug markets — sold as a substitute for MDA and LSD — prompted toxicological investigation. The first US deaths were reported in 1972, followed by nine fatalities among young users in Ontario, Canada between March and August 1973.[5]
Prohibition and death clusters
The Ontario deaths prompted rapid scheduling: the US classified PMA as Schedule I in September 1973,[12] and the United Kingdom followed in 1977.[13] PMA largely vanished during the 1980s but resurfaced in South Australia in the early 1990s, again sold as MDMA, where it earned the street name "death".[6][14]
Modern resurgences
Between 2000 and 2001, approximately 20 deaths worldwide were linked to PMA sold as ecstasy.[5] The most concentrated epidemic struck Norway in 2010–2011, when 12 fatal PMMA intoxications occurred within a population of 4.8 million.[15] England and Wales recorded 20 deaths in 2012 and 29 in 2013, including seven Scottish fatalities linked to Rolex-branded tablets.[5] PMA persists in the ecstasy supply because its precursor, anethole — a constituent of anise oil — is cheap and largely uncontrolled, unlike MDMA's watched precursors.[16]
The name para-methoxyamphetamine denotes the compound's defining structural feature: a methoxy group at the para (4-) position of the amphetamine phenyl ring. The abbreviation PMA and the alternate designation 4-MA are used interchangeably in both scientific and forensic literature.
Chemistry[edit]
Structural class
PMA is a ring-substituted phenethylamine bearing a methoxy group at the para (4-) position of the phenyl ring. This single substitution distinguishes it from MDMA and MDA, which carry a methylenedioxy bridge, and from its N-methylated congener PMMA, of which PMA is also a metabolite.[17] The para-methoxy group confers PMA's defining pharmacological property — potent MAO-A inhibition — which is absent from the methylenedioxy series.
Molecular properties
| Molecular formula | C₁₀H₁₅NO |
| Molecular weight | 165.23 g/mol |
Stereochemistry
PMA possesses a chirality center at the α-carbon of its propylamine chain and exists as a racemic mixture of R- and S-enantiomers. Street-level preparations contain both forms. No studies have investigated whether the enantiomers differ in potency or toxicity — a notable gap given that related amphetamines show significant stereoselective differences.
Synthesis
PMA is synthesized via the Leuckart reaction from 4-methoxyphenylacetone, a precursor derived from anethole — a natural constituent of anise oil.[16] Anethole is cheap and largely unwatched by precursor control regimes, explaining PMA's persistence as an ecstasy adulterant. Characteristic synthesis impurities, including 4-methoxyphenol, serve as forensic markers for identifying clandestine production.[16]
Pharmacology[edit]
Mechanism of action
PMA elevates brain serotonin through three simultaneous mechanisms, a convergence that distinguishes it from MDMA and explains its disproportionate toxicity.
First, PMA is a potent reversible inhibitor of MAO-A — the enzyme responsible for breaking down serotonin — with over 20 times the inhibitory potency of amphetamine.[2] This blockade prevents normal serotonin metabolism, allowing released serotonin to accumulate unchecked.
Second, PMA enters serotonin neurons through the SERT (SERT) and triggers carrier-mediated serotonin release into the synapse. In rat studies, PMA elevated extracellular serotonin to approximately 360% of baseline in the striatum[3] and over 700% in the substantia nigra.[18]
Third, PMA blocks the reuptake of serotonin back into neurons, trapping it in the synapse. In brain regions where only SERT clears serotonin, PMA is a more effective reuptake blocker than MDMA.[4] The combined result — release, reuptake blockade, and metabolic blockade — produces a serotonergic burden far greater than any single mechanism would generate.
Adding an external monoamine oxidase inhibitor does not further increase PMA-induced serotonin release, because PMA already saturates endogenous MAO-A at active doses.[18] PMA also releases dopamine and norepinephrine in the striatum, nucleus accumbens, and frontal cortex,[19] contributing to its stimulant properties, though dopamine release is modest compared to classical stimulants.
Pharmacological classification
PMA's classification is contested. It has been categorized as a serotonergic entactogen similar to MDMA,[20] and as a hallucinogen based on rat behavioral analysis,[7] with partial cross-generalization to LSD in discrimination studies.[21] The US DEA classifies PMA as a Schedule I hallucinogen.[12]
Pharmacokinetics
No controlled human pharmacokinetic studies exist for PMA. All kinetic data come from case reports and animal work.
PMA is taken primarily by mouth, with snorted and injected use occasionally reported.[11] Oral onset is markedly slower than MDMA — 60–90 minutes to over two hours before effects appear.[10][1][5] This delay is the central factor in PMA's danger profile, as users frequently redose before initial effects manifest.
PMA is a metabolite of PMMA via N-demethylation, and the liver enzyme CYP2D6 is involved in this conversion.[17] By structural analogy, CYP2D6 likely plays a role in PMA's own metabolism, but no human data for half-life, bioavailability, or volume of distribution have been published.
Neuroscience[edit]
Where it acts
PMA's triple mechanism — serotonin release, reuptake blockade, and MAO-A inhibition — produces massive extracellular serotonin accumulation across multiple brain regions. The striatum sees serotonin rise to approximately 360% of baseline; the substantia nigra to over 700%.[3][18] In the hippocampus, where only SERT clears serotonin, PMA blocks serotonin removal more effectively than MDMA.[4]
PMA also disrupts thermoregulatory circuits more severely than MDMA, cocaine, or methamphetamine.[8] The massive serotonin surge overwhelms the hypothalamus's temperature set-point regulation, and hot environments dramatically amplify this effect — at 30°C versus 22°C, the combination of PMA and a MAO-A inhibitor produced nearly five-fold higher serotonin outflow.[22]
Why it matters
PMA exemplifies the convergent model of serotonin syndrome: when release, reuptake blockade, and metabolic blockade operate simultaneously, homeostatic regulation fails catastrophically.[18] This framework explains why PMA is more dangerous than substances that elevate serotonin through only one or two pathways.
Repeated PMA exposure reduces serotonin transporter binding by 53% without depleting serotonin itself[23] — a pattern suggesting functional transporter down-regulation rather than the structural nerve damage seen with MDMA. No markers of cytoskeletal disruption were detected,[24] reinforcing the distinction between PMA's tolerance mechanism and MDMA's neurotoxicity.
Several fundamental gaps remain. PMA's specific binding affinities at key receptors (5-HT₂A, DAT, NET) have not been measured, preventing rigorous pharmacological classification. No data exist on whether PMA drives neuroplasticity through BDNF or mTOR pathways, as observed with other serotonergic compounds.
Subjective Effects[edit]
PMA's experiential character sits uneasily between empathogen and stimulant — a diffuse warmth and emotional openness emerge, but they are overlaid with bodily heaviness and cardiovascular strain that intensify with dose.[8][4] The experience is heavily modulated by environment: hot, crowded settings dramatically amplify both subjective intensity and physiological danger.[22] Across all doses, the defining experiential feature is the unusually slow onset, which separates PMA from virtually every substance it might be mistaken for.
Compared to MDMA, PMA delivers less euphoria and emotional closeness but more severe physical effects — the reward-to-risk ratio is substantially worse.[8] Users who have knowingly compared the two consistently describe PMA as a less rewarding, more physically punishing experience, with the entactogenic warmth muted and the body load amplified.
Effect Grid
The full subjective profile manifests: moderate stimulation, emotional warmth and feelings of closeness, heightened sensory perception, and possible visual disturbances consistent with PMA's partial hallucinogenic classification. Cognitive euphoria and prosocial effects reach their clearest expression.
Physical effects intensify: tachycardia, elevated blood pressure, sweating, bruxism, and pupil dilation become pronounced. Body temperature begins to rise noticeably. Nausea and dizziness may occur. Duration extends to an estimated 6–8+ hours.
At this range, PMA's narrow therapeutic window becomes critically relevant. Any additional dosing risks crossing into dangerous territory. Hot environments and physical exertion amplify hyperthermia risk.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual drifting · Tracers · Visual haze / noise
Pupil dilation · Wakefulness · Dehydration sensation · Vasoconstriction · Dry mouth · Heart rate perception changes · Restlessness · Body high · Insomnia · Muscle tension · Physical fatigue · Respiratory stimulation · Dizziness · Nausea · Headache · Trembling · Seizure threshold reduction · Bruxism · Sexual arousal suppression · Motor control impairment · Nystagmus (eye wobbles) · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Vomiting · Involuntary body movements
Dry mouth · Heart rate perception changes · Restlessness · Body high · Insomnia · Muscle tension · Physical fatigue · Respiratory stimulation · Dizziness · Nausea · Headache · Trembling · Seizure threshold reduction · Bruxism · Sexual arousal suppression · Motor control impairment · Nystagmus (eye wobbles) · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Vomiting · Involuntary body movements
Cognitive impairment · Confusion · Analysis enhancement · Focus enhancement · Information processing enhancement · Motivation enhancement · Aesthetic enhancement · Cognitive dysphoria · Decision impairment · Thought disorganization · Thought loops · Delirium
Focus enhancement · Information processing enhancement · Motivation enhancement · Aesthetic enhancement · Cognitive dysphoria · Thought disorganization · Thought loops · Delirium
Emotional enhancement · Empathy enhancement · Irritability · Anhedonia · Emotional lability · Mania
Anhedonia · Emotional lability
Communication enhancement · Craving · Emotional susceptibility · Trust enhancement
Timeline
First alerts are subtle and delayed — mild restlessness or slight mood shift. This prolonged onset (60–120 minutes) is the defining danger: users accustomed to MDMA's 30–60 minute onset frequently re-dose during this window.
Stimulation builds gradually with emerging emotional warmth and sensory enhancement. Tachycardia, pupil dilation, and jaw tension become noticeable. Rising body temperature begins.
Maximum stimulation, emotional intensity, and sensory effects. Hyperthermia risk is highest during this phase. Visual disturbances and prosocial effects are most pronounced.
Effects sustain at diminishing intensity. Stimulation and emotional effects persist but begin to recede. Physical discomfort (jaw tension, temperature dysregulation) may become more prominent as subjective reward diminishes.
Gradual return toward baseline over 1–2 hours. Residual stimulation, fatigue, and emotional flatness. Appetite remains suppressed.
Residual effects include fatigue, mood depression, irritability, appetite suppression, and difficulty concentrating. Sleep may remain disrupted for several hours.
⚠ Avoid driving or operating machinery for at least 12 hours after effects begin to subside, as residual impairment and fatigue persist beyond subjective resolution.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- None
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- MDMA · PMMA · MDA
Toxicity
Acute toxicity
PMA is among the most acutely dangerous substances found in the ecstasy supply. The margin between an active and a fatal dose is narrow — fatal blood concentrations start as low as 0.57 mg/L in polydrug cases.[1][25][26] PMA is consistently characterized as significantly more toxic than MDMA at equivalent doses.[4][8]
PMA is among the most dangerous substances encountered in the ecstasy/MDMA supply. The narrow margin between active and lethal doses, combined with delayed onset that promotes re-dosing, creates an acute overdose risk not present with MDMA itself.
The primary mechanisms of death documented in forensic cases are:
- Hyperthermia: Core body temperatures exceeding 40–42°C, more severe than MDMA, cocaine, or methamphetamine[10][11][8]
- Cardiovascular collapse: The most frequently cited cause of death in forensic studies[1][14][25]
- Seizures: Generalized convulsions in multiple fatal and near-fatal cases[10][15]
- Multi-organ failure: Including muscle breakdown, acute kidney failure, liver failure, and widespread blood clotting dysfunction[25][27][11]
- Respiratory failure[15]
Serotonin syndrome
Clinical presentations of PMA poisoning are consistent with serotonin syndrome: high body temperature, muscle rigidity, agitation, rapid heart rate, and heavy sweating. PMA/PMMA exposure has been explicitly described as producing multi-organ dysfunction and serotonin syndrome followed by cardiovascular collapse.[27]
Electrolyte disturbances
Low blood sugar and high potassium levels appear specific to PMA poisoning and may represent independent risk factors in fatal cases.[10]
Muscle breakdown
Amphetamine-class intoxication carries a pooled muscle breakdown incidence of approximately 30%.[28] PMA-specific rates have not been separately reported but are expected within or above this range given its more severe serotonergic toxicity.
Psychological Risks
No controlled studies have assessed psychological effects of PMA in humans. Case reports describe dose-dependent anxiety and agitation,[11] with animal models confirming anxiogenic effects at higher doses.[29]
Reported comedown effects include anxiety, irritability, depression, sleep disruption, appetite suppression, concentration difficulties, and paranoia.[11] The psychological risk profile is dominated by the acute danger of serotonergic crisis rather than long-term psychiatric effects. No data address PMA-induced psychosis or lasting psychological destabilization.
Tolerance & Dependence
Tolerance
Repeated PMA administration reduces SERT binding by 53% without depleting serotonin itself.[23] This transporter down-regulation could reduce PMA's effects with repeated use, potentially driving dose escalation — a particularly dangerous pattern given the narrow margin between active and lethal doses. No human tolerance data exist.citation needed
Dependence
PMA does not maintain self-administration in rats and shows only weak similarity to amphetamine in discrimination tests, indicating low reinforcing potential.[9] PMA also failed to substitute for amphetamine in primate studies.[30]
Physical withdrawal has not been documented.[11] No human data specifically address PMA dependence or addiction.
Drug Interactions
PMA's triple serotonergic mechanism — MAO-A inhibition, serotonin release, and reuptake blockade — makes it exceptionally dangerous in combination with any substance that further elevates serotonin or amplifies cardiovascular and hyperthermic effects.
MAO inhibitor combinations
PMA is itself a potent MAO-A inhibitor.[2] Combining it with any external monoamine oxidase inhibitor — reversible (moclobemide) or irreversible (phenelzine, tranylcypromine) — compounds the blockade. At elevated ambient temperature (30°C), moclobemide combined with PMA produced 1450% peak serotonin elevation and sustained dangerous hyperthermia.[22][3]
Serotonergic drugs
Any drug that increases serotonin — including tramadol, SSRIs, and SNRIs — carries severe serotonin syndrome risk when combined with PMA.safety citation needed MDMA combined with PMA is documented in multiple fatalities[25][31]: PMA's slow onset and MDMA's faster onset mean users may unknowingly combine both when redosing.
Stimulants
Cocaine, methamphetamine, and other stimulants carry additive cardiovascular and hyperthermia risk when combined with PMA.[11]
Cannabis and alcohol
Cannabis may increase anxiety and paranoia risk; alcohol amplifies negative effects.[11] No pharmacokinetic interaction data exist for either combination.
Contraindications
PMA's pharmacological profile — potent MAO-A inhibition combined with serotonin release and reuptake blockade — creates absolute contraindications for any concurrent medication or condition that compounds serotonergic, cardiovascular, or thermoregulatory risk.
Concurrent MAO inhibitor therapy (including moclobemide, phenelzine, tranylcypromine, selegiline) is an absolute contraindication: the combination dramatically amplifies serotonin syndrome risk and can be lethal at any PMA dose.[3][22]
Cardiovascular conditions including high blood pressure, heart rhythm disorders, and structural heart disease are absolute contraindications given PMA's documented mechanism of death via cardiovascular collapse.[11]
Epilepsy is contraindicated given documented seizures in PMA poisoning.[10][15]
Respiratory conditions are relative contraindications given respiratory failure as a documented mechanism of death.[11]
Liver and kidney impairment are relative contraindications given multi-organ failure in severe toxicity cases and the likely hepatic metabolism of PMA.[17]
Harm Reduction[edit]
Forms & Identification
PMA is almost never sold under its own name. It appears in tablets marketed as MDMA or ecstasy, often with branding identical to legitimate MDMA pills — including logos linked to fatality clusters such as "Red Mitsubishi" and Rolex crown stamps.[5] The substance cannot be distinguished from MDMA by appearance, taste, or smell.
Reagent testing is essential: PMA reacts differently from MDMA with standard field kits, making it identifiable before ingestion. Drug checking services, where available, provide the most reliable identification and should be used whenever possible.
Guidelines
- Test every tablet or powder with reagent kits before use — PMA is visually indistinguishable from MDMA
- Start with the lowest possible dose and do not redose for at least 2–3 hours — PMA's onset is far slower than MDMA
- Use in cool environments with good ventilation; avoid crowded, hot venues
- Stay hydrated but do not overdrink — sip water steadily rather than consuming large amounts
- Have a sober, informed companion present who knows what was taken and when
- Monitor body temperature; if skin feels unusually hot to the touch, begin active cooling immediately
- Know the location of the nearest medical facility before the session begins
Set & Setting
PMA's danger is dramatically amplified by environment. Hot, crowded venues — nightclubs, festivals, densely packed events — increase the risk of lethal hyperthermia by magnifying PMA's disruption of thermoregulation.[22][8] Cool, calm environments with access to water and ventilation substantially reduce physiological risk.
PMA's delayed onset (60–120+ minutes) means effects may not appear until well into an event. Anxiety about the delay frequently drives dangerous decisions. Anyone who has taken a substance believed to be MDMA and feels nothing after an hour should not redose — a second dose taken before the first manifests is the single most documented pathway to PMA fatality.[11]
Aftercare & integration. PMA produces a significant physical and psychological comedown. In the days following use, expect fatigue, irritability, low mood, disrupted sleep, and reduced appetite.[11] These effects reflect serotonin depletion and typically resolve within a week.
Prioritize sleep, adequate nutrition, and gentle physical activity during recovery. Avoid all serotonergic substances — including MDMA, other empathogens, and serotonergic medications — for at least several weeks to allow serotonin systems to normalize. If anxiety, depression, or paranoia persist beyond 7–10 days, seek professional support.
Recovery & Support
PMA carries low abuse liability — it is not typically a drug of compulsive use.[9] Repeated exposure is more commonly a consequence of its presence as an MDMA adulterant than intentional seeking. However, anyone using empathogens or stimulants frequently should be attentive to patterns of escalating use, emotional reliance, or difficulty functioning without substances.
Support resources for stimulant and empathogen use include local drug and alcohol services, national helplines, and peer support groups. Drug checking services can reduce harm by identifying PMA before it is consumed.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Body temperature that can be felt radiating through clothing. Rigid or jerking muscles. Seizure. Loss of consciousness. Rapid or irregular heartbeat. Confusion or agitation that escalates rather than resolves. Any of these after taking a substance believed to be MDMA demands immediate medical attention.
Immediate steps:
- 1. Call emergency services immediately — PMA toxicity escalates rapidly and cannot be managed without medical intervention
- 2. Move the person to the coolest available environment
- 3. Remove excess clothing and apply cool (not ice-cold) water to skin, especially neck, armpits, and groin
- 4. Place an unconscious person in the recovery position (on their side, airway clear)
- 5. Do not induce vomiting
- 6. Do not give aspirin or paracetamol — these do not treat drug-induced hyperthermia and may worsen organ damage
- 7. Stay with the person until help arrives
What to tell the dispatcher: Name the substance (PMA or ecstasy/MDMA), estimated amount and time taken, and current symptoms — especially body temperature, seizures, or loss of consciousness. Good Samaritan laws in many jurisdictions protect people who call for help during drug emergencies.
Legal Status[edit]
PMA is subject to the highest level of drug control in virtually every jurisdiction where it has been specifically scheduled. It is listed under Schedule I of the United Nations Convention on Psychotropic Substances, reflecting international consensus that PMA has no accepted medical use and carries significant risk of harm. PMA was among the earliest substituted amphetamines to be specifically controlled, with US scheduling in 1973 and UK scheduling in 1977, both prompted directly by documented fatalities.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Classified as a hallucinogen. Effective September 21, 1973[12] |
| United Kingdom | Class A, Schedule 1 (Misuse of Drugs Act 1971) | Controlled under phenethylamine structural clause. Effective September 20, 1977[13] |
| Australia | Schedule 9 (Prohibited Substance) | Poisons Standard[11] |
| Germany | Highest control level (BtMG) | Controlled since September 1999[32] |
| Canada | Schedule I (CDSA) | Added in 2012 following documented fatalities[32] |
| New Zealand | Class A (Misuse of Drugs Act) | Highest classification[32] |
| International | Schedule I (UN Convention on Psychotropic Substances) | No accepted medical use; highest international control level |
PMA is directly scheduled in all major jurisdictions; structural analog act applicability is not relevant, as the substance itself is specifically named in scheduling instruments.
references
- [1] ^abcdRojek S, Bochełała F, Kula K, Maciów-Głąb M, Kłys M (2016) Medicolegal aspects of PMA-related deaths. — Legal Medicine (Tokyo) doi:10.1016/j.legalmed.2016.06.002
- [2] ^abcGreen AL, El Hait MA (1980) p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. — The Journal of Pharmacy and Pharmacology PMID:6103055
- [3]
- [4]
- [5]
- [6] ^abByard RW, Gilbert J, James R, Lokan RJ (1998) Amphetamine derivative fatalities in South Australia--is 'Ecstasy' the culprit? — The American Journal of Forensic Medicine and Pathology PMID:9760094